ReviewCurrent rheumatology reports2021
IgA Vasculitis in Adults: a Rare yet Challenging Disease.
Review in Current rheumatology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Evidence-based guidelines for the diagnosis and management of adult-onset IgA vasculitis.Nature reviews. Rheumatology · 2026Guideline
- The efficacy of rituximab in the treatment of IgA vasculitis nephritis.Clinical and experimental medicine · 2024Pooled it
- Fulminant Multisystem IgA Vasculitis With Diffuse Alveolar Hemorrhage, Severe Gastrointestinal Hemorrhage, Paralytic Ileus, and Renal Involvement in an Adolescent: A Case Report.Clinical case reports · 2026Article
- Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.Current opinion in rheumatology · 2026Review
- A Woman With a Rash and Abdominal Pain.Journal of the American College of Emergency Physicians open · 2026Review
- Beyond the Scope and Scan: A Case of Adult-Onset IgA Vasculitis Presenting with Gastrointestinal Predominance.Digestive diseases and sciences · 2026Article
- Review
- Recurrent immunoglobulin A vasculitis in children and adolescents: prevalence and associated risk factors.Clinical and experimental pediatrics · 2026Article
- IgA Vasculitis Across the Ages: Is It Time for a Precision Medicine Approach?ACR open rheumatology · 2025Review
- Exhausted natural killer cells in adult IgA vasculitis.Arthritis research & therapy · 2025Article
- Major Cardiovascular and Renal Complications in IgA Vasculitis: Insights from a Federated Health Research Network.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2025Article
- Predictors of Abdominal Pain Duration in Henoch-Schönlein Purpura and Nomogram Model Development: A Retrospective Study of 220 Cases.Journal of inflammation research · 2025Article
- Article
- Abdominal imaging and endoscopic characteristics of adult abdominal IgA vasculitis: a multicenter retrospective study.Annals of medicine · 2024Article
- IgA Vasculitis (Henoch-Schönlein Purpura): An Update on Treatment.Journal of clinical medicine · 2024Review
- SARS-CoV-2 as a trigger of IgA vasculitis: a clinical case and literature review.Rheumatology international · 2024Review
- An Unusual Complication of Lisinopril: A Report of Iatrogenic Henoch-Schönlein Purpura.Cureus · 2024Article
- Navigating Adult-Onset IgA Vasculitis-Associated Nephritis.Life (Basel, Switzerland) · 2024Review
- IgA vasculitis after COVID-19: a case-based review.Rheumatology international · 2024Review
- Steroid-Dependent Recurrent IgA Vasculitis in a 19-Year-Old Woman.HCA healthcare journal of medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIgA vasculitis (IgAV) is a rare and poorly understood systemic vasculitis in adults. Its diagnosis and treatment remain a challenge. Herein, we review the clinical manifestations, diagnosis, management, and prognosis of IgAV in adults. RECENT
findingsThe clinical course of IgAV in adults appears to be different from pediatric IgAV, especially due to its higher risk of evolving into end-stage renal disease. Rising awareness and interest in adult-onset IgA vasculitis has resulted in recent increasing number of publications on different treatment experiences. However, there is still controversy over the role of glucocorticoid (GC) and different immunosuppressive therapies such as cyclophosphamide, rituximab, and mychophenolate mofetil for more severe IgAV. Data regarding potential benefits of targeting the mucosal immune system, toll-like receptors, complements, and tyrosine kinase inhibitors in the treatment of IgA nephropathy are emerging. High quality evidence or guidelines in the treatment of severe IgAV are lacking and there is still a great need for controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.